A dataset for the analysis of antibody response to glycan alpha-Gal in individuals with immune-mediated disorders

de la Fuente, José; Urra, José Miguel; Contreras, Marinela; Pacheco, Iván; Ferreras-Colino, Elisa; Doncel-Pérez, Ernesto; Fernández de Mera, Isabel G.; Villar, Margarita; Cabrera, Carmen M.; Gómez Hernando, Cesar; Vargas Baquero, Eduardo; Blanco García, Javier; Rodríguez Gómez, Javier; Velayos Galán, Alberto; Feo Brito, Francisco; Gómez Torrijos, Elisa; Cabezas-Cruz, Alejandro; Gortázar, Christian

Humans evolved by losing the capacity to synthesize the glycan Galα1-3Galβ1-(3)4GlcNAc-R (α-Gal), which resulted in the development of a protective response mediated by anti-α-Gal IgM/IgG/IgA antibodies against pathogens containing this modification on membrane proteins. As an evolutionary trade-off, humans can develop the alpha-Gal syndrome (AGS), a recently diagnosed disease mediated by anti-α-Gal IgE antibodies and associated with allergic reactions to mammalian meat consumption and tick bites. However, the anti-α-Gal antibody response may be associated with other immune-mediated disorders such as those occurring in patients with COVID-19 and Guillain-Barré syndrome (GBS). Here, we provide a dataset (209 entries) on the IgE/IgM/IgG/IgA anti-α-Gal antibody response in healthy individuals and patients diagnosed with AGS, tick-borne allergies, GBS and COVID-19. The data allows correlative analyses of the anti-α-Gal antibody response with factors such as patient and clinical characteristics, record of tick bites, blood group, age and sex. These analyses could provide insights into the role of anti-α-Gal antibody response in disease symptomatology and possible protective mechanisms.